Analyst firms · H.C. Wainwright · DCPH

H.C. Wainwright DCPH price target and rating history

Deciphera Pharmaceuticals Inc. (DCPH) · Health Care

H.C. Wainwright rates Deciphera Pharmaceuticals Inc. (DCPH) Buy with a $15 price target, as of its latest action on Dec 1, 2021. It has published 3 rating actions on DCPH since August 2021, including 0 upgrades and 0 downgrades.

Current rating
Buy
Price target
$15
Median target, all firms
Too few
Actions on DCPH
3

H.C. Wainwright price target on DCPH

$70$43$1520222023202420252026
H.C. Wainwright price target on DCPH, each point a stated target, August 2021 to December 2021.

Every H.C. Wainwright rating on DCPH

Questions about H.C. Wainwright and DCPH

What is H.C. Wainwright's price target for DCPH?
H.C. Wainwright's latest stated price target for Deciphera Pharmaceuticals Inc. (DCPH) is $15, from its action on Dec 1, 2021.
What is H.C. Wainwright's rating on DCPH?
H.C. Wainwright rates DCPH Buy, a bullish rating, as of Dec 1, 2021.
When did H.C. Wainwright last change its view on DCPH?
On Dec 1, 2021, H.C. Wainwright cuts its price target to $15 from $25, keeps Buy.

More DCPH rating histories

All H.C. Wainwright ratingsDCPH news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.